Lung cancer is the second most common malignancy, accounting for more than one-quarter of all cancer deaths in the United States. Despite the unremitting efforts toward biomarker discovery and the development of targeted therapy and immunotherapy, lung cancer is by far the leading cause of cancer death with poor prognosis.
Past research has determined that aminoacyl-tRNA synthetase-interacting multi-functional protein 2 (AIMP2) works as potent tumour suppressor, while its splicing variant lacking exon 2 (AIMP2-DX2) competes with AIMP2 for binding to target proteins and compromises its anti-tumour activity.
A study led by Dr. Ji Ye Jung at the Yonsei University College of Medicine in South Korea investigated the diagnostic and prognostic usefulness of autoantibodies against AIMP2 and AIMP2-DX2 by measuring their serum levels in 80 normal and lung cancer samples that were matched in age, gender and smoking status. The researchers found that autoantibodies against AIMP2-DX2 and AIMP2 were detectable in blood. The increased ratio of AIMP2-DX2/AIMP2 autoantibodies was related to the poor clinical outcome of lung cancer patients.
The results from this study suggest that the ratio of AIMP2-DX2/AIMP2 autoantibodies is a potential prognostic marker in lung cancer. Further studies need to be done to support the results from this study.